HK1250662A1 - 用於治療癌症的免疫原性融合蛋白 - Google Patents

用於治療癌症的免疫原性融合蛋白

Info

Publication number
HK1250662A1
HK1250662A1 HK18110240.7A HK18110240A HK1250662A1 HK 1250662 A1 HK1250662 A1 HK 1250662A1 HK 18110240 A HK18110240 A HK 18110240A HK 1250662 A1 HK1250662 A1 HK 1250662A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
fusion proteins
immunogenic fusion
immunogenic
Prior art date
Application number
HK18110240.7A
Other languages
English (en)
Inventor
Dirk G Brockstedt
Peter M Lauer
William G Hanson
Meredith Lai Ling Leong
Marcella Fasso
Christopher Steven Rae
Charles G Drake
Original Assignee
Aduro Biotech Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc, Univ Johns Hopkins filed Critical Aduro Biotech Inc
Publication of HK1250662A1 publication Critical patent/HK1250662A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18110240.7A 2015-04-13 2018-08-09 用於治療癌症的免疫原性融合蛋白 HK1250662A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562146626P 2015-04-13 2015-04-13
US201562146654P 2015-04-13 2015-04-13
US201562263174P 2015-12-04 2015-12-04
PCT/US2016/027167 WO2016168214A2 (en) 2015-04-13 2016-04-12 Immunogenic fusion proteins for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1250662A1 true HK1250662A1 (zh) 2019-01-11

Family

ID=55808893

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18110072.0A HK1250731A1 (zh) 2015-04-13 2018-08-06 用於治療癌症的免疫原性融合蛋白
HK18110240.7A HK1250662A1 (zh) 2015-04-13 2018-08-09 用於治療癌症的免疫原性融合蛋白

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18110072.0A HK1250731A1 (zh) 2015-04-13 2018-08-06 用於治療癌症的免疫原性融合蛋白

Country Status (11)

Country Link
US (2) US9808516B2 (zh)
EP (1) EP3283100A2 (zh)
JP (1) JP2018512165A (zh)
CN (1) CN107980044A (zh)
AU (1) AU2016247894A1 (zh)
CA (1) CA2982543A1 (zh)
HK (2) HK1250731A1 (zh)
MA (1) MA44378A (zh)
TW (1) TW201704267A (zh)
UY (1) UY36617A (zh)
WO (1) WO2016168214A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
TW201704267A (zh) 2015-04-13 2017-02-01 奧都羅生技公司 用於治療癌症的免疫性融合蛋白
TW201710285A (zh) 2015-04-13 2017-03-16 奧都羅生技公司 表皮生長因子受體變體ｉｉｉ－間皮素融合物及使用其之方法
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
CN118290563B (zh) * 2024-06-03 2024-08-02 磐如生物科技(天津)有限公司 一种前列腺癌抗原肽和免疫佐剂组合物及其在抗肿瘤中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
JP4620808B2 (ja) 1994-11-28 2011-01-26 トーマス・ジェファーソン・ユニバーシティ 突然変異上皮成長因子受容体を標的とする試薬および方法
EP1303299B1 (en) 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
EP2311978A1 (en) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
JP4839209B2 (ja) 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
PT1592441E (pt) 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
AU2004249254B2 (en) 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
DK1991263T3 (en) 2006-03-01 2015-03-30 Aduro Biotech Prepared listeria and methods of use thereof
WO2012068360A1 (en) 2010-11-17 2012-05-24 Aduro Biotech Methods and compositions for inducing an immune response to egfrviii
CA2832307A1 (en) * 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2938627B1 (en) 2012-12-27 2019-03-20 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
CN104211814A (zh) 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
TW201710285A (zh) 2015-04-13 2017-03-16 奧都羅生技公司 表皮生長因子受體變體ｉｉｉ－間皮素融合物及使用其之方法
TW201704267A (zh) 2015-04-13 2017-02-01 奧都羅生技公司 用於治療癌症的免疫性融合蛋白

Also Published As

Publication number Publication date
TW201704267A (zh) 2017-02-01
EP3283100A2 (en) 2018-02-21
CN107980044A (zh) 2018-05-01
US20180085446A1 (en) 2018-03-29
US9808516B2 (en) 2017-11-07
MA44378A (fr) 2019-01-23
JP2018512165A (ja) 2018-05-17
US20160324945A1 (en) 2016-11-10
HK1250731A1 (zh) 2019-01-11
WO2016168214A2 (en) 2016-10-20
AU2016247894A1 (en) 2017-10-26
UY36617A (es) 2016-10-31
CA2982543A1 (en) 2016-10-20
WO2016168214A3 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
IL259996A (en) Combinations for cancer treatment
LT3473263T (lt) Kombinuoti preparatai, skirti vėžio gydymui
RS61536B1 (sr) Kombinacije fgfr- i cmet-inhibitora za lečenje kancera
HK1250662A1 (zh) 用於治療癌症的免疫原性融合蛋白
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
ZA201902689B (en) Therapeutic protein
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
IL265751A (en) Immunogenic compounds for cancer treatment
EP3139955A4 (en) Fusion proteins for treating cancer and related methods
IL277377B (en) Prohemostatic proteins for the treatment of bleeding
IL263564B (en) Peptides for the treatment of osteoarthritis
IL249610A0 (en) Chimeric proteins for cancer treatment
ZA201608886B (en) Human cytolytic fusion proteins
EP3261673B8 (en) Combined vaccination/radioterapy for cancer treatment
GB201616715D0 (en) Therapeutic protein
AU2015904120A0 (en) Selection methods for the treatment of cancer